CompletedPhase NA

Semaglutide and Intestinal Iron Absorption

The Effect of Parenterally Administred Semaglutide on Intestinal Iron Absorption in Individuals With Type 2 Diabetes Mellitus

Lead sponsor

University Hospital Dubrava

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

•HbA1c ≥7%

Primary endpoint

•General objective

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06629688

Org study IDsema-iron

Timeline

Milestones

Study start2023-11-01actual

Primary completion2024-04-01actual

Study completion2024-04-01actual

Study first posted2024-10-08actual

Last update posted2024-12-05actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age45 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•T2DM patients

•ages between 45 and 65

•with poorly managed T2DM (HbA1c ≥ 7%)

•who are candidates for treatment intensification and beginning of parenterally administered semaglutide

Exclusion criteria

•hypersensitivity to GLP-1 RAs,

•adequately controlled with current glucose-lowering medications,

•already treated with GLP-1 RA,

•type 1 diabetes mellitus or any other form of diabetes,

•hemochromatosis,

•iron deficiency anaemia,

•sideropaenia,

•severe chronic illnesses,

•malignant neoplasms of any site,

•chronic infectious diseases,

•chronic rheumatic inflammatory diseases,

•malabsorption syndrome,

•inflammatory bowel disease,

•history of gastrointestinal tract reduction surgery,

•medications that interfere with absorption,

•perimenopausal women

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

3 endpoints

Primary/protocol endpoint/low confidence

General objective

Time frame:10 weeks

threshold achievement, improvement

Secondary/protocol endpoint/low confidence

Specific objectives

Time frame:10 weeks

descriptive

Other/protocol endpoint/low confidence

Sex differences

Time frame:10 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.